Par­ty on: Base edit­ing start­up, com­pu­ta­tion­al drug dis­cov­ery ex­perts and CRO bag close to $2B to­tal on their way to Nas­daq

On the back of Black Di­a­mond Ther­a­peu­tics’ roar­ing pub­lic de­but, the IPO mo­men­tum is push­ing three biotech play­ers from very dif­fer­ent cor­ners of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.